Imatinib-induced pyoderma gangrenosum in a patient with chronic myeloid leukemia

Indian J Dermatol Venereol Leprol. 2021 Sep-Oct;87(5):704-706. doi: 10.25259/IJDVL_1158_20.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Female
  • Humans
  • Imatinib Mesylate / adverse effects*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Middle Aged
  • Pyoderma Gangrenosum / chemically induced*
  • Pyoderma Gangrenosum / pathology*

Substances

  • Antineoplastic Agents
  • Imatinib Mesylate